Analyst firms · Barclays · SRPT
Barclays SRPT price target and rating history
Sarepta Therapeutics Inc. (SRPT) · Health Care
Barclays rates Sarepta Therapeutics Inc. (SRPT) Equal Weight with a $20 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on SRPT since July 2025, including 1 upgrade and 2 downgrades. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50. Barclays's $20 is 15% below that.
- Current rating
- Equal Weight
- Price target
- $20
- Median target, all firms
- $23.50
- Actions on SRPT
- 4
Barclays price target on SRPT
Every Barclays rating on SRPT
- Jan 28, 2026
- Jul 29, 2025
- Jul 28, 2025
- Jul 22, 2025
How other firms rate SRPT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Hold | $18 | Nov 10, 2026 |
| Wolfe Research | Outperform | $27 | Jul 9, 2026 |
| Barclays | Equal Weight | $20 | Jan 28, 2026 |
| Wedbush | Outperform | $32 | Dec 9, 2025 |
Questions about Barclays and SRPT
- What is Barclays's price target for SRPT?
- Barclays's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $20, from its action on Jan 28, 2026.
- What is Barclays's rating on SRPT?
- Barclays rates SRPT Equal Weight, a neutral rating, as of Jan 28, 2026.
- When did Barclays last change its view on SRPT?
- On Jan 28, 2026, Barclays resumes coverage at Equal Weight, price target $20.
- How does Barclays's SRPT target compare with other analysts?
- Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50. Barclays's $20 is 15% below that.
More SRPT rating histories
- Deutsche Bank4
- BMO Capital Markets3
- Oppenheimer4
- H.C. Wainwright4
- Citigroup4
- Needham5
- Morgan Stanley6
- Cantor Fitzgerald4
- RBC Capital Markets5
- Credit Suisse3
All Barclays ratingsSRPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.